Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Publication|Articles|July 16, 2025
Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic
Author(s)Ashling Wahner
Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.
Advertisement
Advertisement
As the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting drew to a close, top experts across oncology fields reflected on the data that signaled future developments regarding novel biomarker testing strategies, increasingly personalized modifications of standard chemotherapy regimens, and optimal use of PD-1/PD-L1 inhibition.
Related to this article
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
Advertisement
Advertisement